findmyKOL
Clinical trialNCT00006152CompletedPhase 2Interventional

A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment42HIV Infections
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to see if adding 1 or 2 drugs to the anti-HIV therapy of patients whose HIV levels increased while taking their anti-HIV drugs can lower viral load (amount of HIV in the blood) and keep it low up to Week 24. (This study has been changed. Previously, only patients whose levels increased on their first round of anti-HIV drugs were being studied.) Anti-HIV drug treatments that contain a combination of 3 or more drugs can lower HIV levels, raise CD4 cell counts, and improve survival. Unfortunately, many patients "fail" their anti-HIV drug treatment when their HIV levels go above 500 copies/ml. Usually the next step is to switch the patient to different anti-HIV drugs. Doctors would like to see whether adding 1 or 2 different drugs to the "failed" treatment also can lower HIV levels. Adding 1 or 2 drugs might be better than switching all of the drugs since patients who take many different drugs can develop drug-resistant HIV. (This study has been changed. Previously, only patients taking protease inhibitors (PI) whose levels increased on their first round of anti-HIV drugs were being studied.)

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Univ of Alabama at Birmingham

    Birmingham, Alabama, United States

  • Univ of Southern California / la County Usc Med Ctr

    Los Angeles, California, United States

  • Univ of California, San Diego

    San Diego, California, United States

  • Univ of Colorado Health Sciences Ctr

    Denver, Colorado, United States

  • Northwestern Univ Med School

    Chicago, Illinois, United States

  • the Core Ctr

    Chicago, Illinois, United States

  • Beth Israel Deaconess - West Campus

    Boston, Massachusetts, United States

  • St Louis Regional Hosp / St Louis Regional Med Ctr

    St Louis, Missouri, United States

  • Beth Israel Med Ctr

    New York, New York, United States

  • Univ of North Carolina

    Chapel Hill, North Carolina, United States

  • Duke Univ Med Ctr

    Durham, North Carolina, United States

  • Julio Arroyo

    West Columbia, South Carolina, United States

  • Univ of Texas Galveston

    Galveston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AbacavirAmprenavirRitonavir
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
—
Primary completion
—
Completion
31 Aug 2002
Last update posted
1 Nov 2021
Registered enrollment
42
Registry id
NCT00006152

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.